Human Trials for AI Symbiosis Kicks Off

Elon Musk, the visionary behind Tesla and SpaceX, has recently made headlines with a groundbreaking venture. Neuralink, a brain-interface-technology company founded by the billionaire entrepreneur, has successfully implanted its inaugural brain-reading device into a human, marking a pivotal moment in the fusion of technology and consciousness.

Elon Musk, renowned for his audacious endeavours such as Mars colonization and subterranean city transport links, now delves into the possibilities presented by this new brain-computer interface (BCI) technology. BCIs, designed to record and decode brain activity, aim to empower paralyzed individuals to effortlessly control computers, wheelchairs, and other devices through mere thought. Initial experiments with monkeys yielded promising results, with a primate named Pager mastering the video game ‘Pong’ using only the power of its mind.

Yet, Neuralink’s ambitions transcend addressing neurological and spinal injuries. Musk envisions a future where humanity and artificial intelligence achieve symbiosis, a concept he deems ‘species-level important.’ This revolutionary leap forward would enable instantaneous internet searches, language translations, and seamless communication with electronic devices through the sheer power of thought.

However, not everyone embraces this technological frontier with open arms. Scepticism arises, questioning whether the benefits of BCI technology outweigh the risks associated with brain surgery. Ethical concerns also linger, fuelled by controversies surrounding Neuralink’s research practices, including allegations of adverse effects on animals and claims of euthanizing monkeys as part of their studies.

As this unique narrative unfolds, the world awaits the outcomes of human trials approved by the US Food and Drug Administration (FDA) in May 2023. These trials aim to determine if Neuralink and Elon Musk have indeed discovered a transformative way to enhance the lives of individuals with disabilities, offering them a novel means of interacting with the world. Musk reports positive progress, citing the recovery and promising signs of neuron spike detection in the first human recipient of the brain chip. The journey into the uncharted territory of human-AI symbiosis has just begun, leaving the world intrigued and eager to witness the unfolding possibilities.

Sources: News24, Business Insider, BBC News

Piece written by Tiaan van Aswegen, Trive Financial Market Analyst

Disclaimer: Trive South Africa (Pty) Ltd (hereinafter referred to as “Trive SA”), with registration number 2005/011130/07, is an authorised Financial Services Provider in terms of the Financial Advisory and Intermediary Services Act, 37 of 2002. Trive SA is authorised and regulated by the South African Financial Sector Conduct Authority (FSCA) and holds FSP number 27231. Trive Financial Services Ltd (hereinafter referred to as “Trive MU”) holds an Investment Dealer (Full-Service Dealer, excluding Underwriting) Licence with licence number GB21026295 pursuant to section 29 of the Securities Act 2005, Rule 4 of the Securities Rules 2007, and the Financial Services Rules 2008. Trive MU is authorized and regulated by the Mauritius Financial Services Commission (FSC) and holds Global Business Licence number GB21026295 under Section 72(6) of the Financial Services Act. Trive SA and Trive MU are collectively known and referred to as “Trive Africa”.

Market and economic conditions are subject to sudden change which may have a material impact on the outcome of financial instruments and may not be suitable for all investors. Trive Africa and its employees assume no liability for any loss or damage (direct, indirect, consequential, or inconsequential) that may be suffered. Please consider the risks involved before you trade or invest. All trades on the Trive Africa platform are subject to the legal terms and conditions to which you agree to be bound. Brand Logos are owned by the respective companies and not by Trive Africa. The use of a company’s brand logo does not represent an endorsement of Trive Africa by the company, nor an endorsement of the company by Trive Africa, nor does it necessarily imply any contractual relationship. Images are for illustrative purposes only and past performance is not necessarily an indication of future performance. No services are offered to stateless persons, persons under the age of 18 years, persons and/or residents of sanctioned countries or any other jurisdiction where the distribution of leveraged instruments is prohibited, and citizens of any state or country where it may be against the law of that country to trade with a South African and/or Mauritius based company and/or where the services are not made available by Trive Africa to hold an account with us. In any case, above all, it is your responsibility to avoid contravening any legislation in the country from where you are at the time.

CFDs and other margin products are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how these products work and whether you can afford to take the high risk of losing your money. Professional clients can lose more than they deposit. See our full Risk Disclosure and Terms of Business for further details. Some or all of the services and products are not offered to citizens or residents of certain jurisdictions where international sanctions or local regulatory requirements restrict or prohibit them.